NEPTUNE enrolls participants into three longitudinal cohorts: biopsy, non-biopsy, and Alport syndrome cohorts. Participants provide blood, urine, and clinical data at enrollment and at 4-6 month intervals. Visits are in-person and by telephone.
Learn more about the NEPTUNE study by referencing our NEPTUNE Overview Slide Deck. Information on the cohorts is also summarized in our One-page Cohort Overview. To aid in determining participant eligibility, reference our Enrollment Triage Chart.
Participants eligible for and interested in NEPTUNE Match are also eligible for enrollment into the NEPTUNE study. The eligibility criteria for NEPTUNE Match are dynamic and will change as new trials are added.
A double-blinded, randomized trial of baricitinib therapy for APOL1-associated focal segmental glomerular sclerosis (FSGS) or Hypertension Associated-CKD
- TRPC6 Inhibition in FSGS
Randomized, double-blind study to investigate the efficacy, safety, and tolerability of BI764198 vs placebo in focal segmental glomerular sclerosis (FSGS).
Open label clinical trial of Sparsentan to evaluate safety and efficacy on proteinuria and kidney function in children with focal segmental glomerular sclerosis (FSGS), minimal change disease, IgAN, IgAV, and Alport syndrome.
- TNF Precision Medicine
A proof of concept, open label clinical trial addressing the treatment of patients with focal segmental glomerular sclerosis (FSGS) or treatment resistant minimal change disease.